ArticleLeukemia2021
Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making.
Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 128 citations in OpenAlex.
- Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial.Nature communications · 2026Trial
- Trial
- Metabolic-inflammatory index CTI identifies high-risk early-stage natural killer/T-cell lymphoma and informs a novel prognostic model.Biomarker research · 2026Article
- Treatment Patterns and Clinical Outcomes After Immunotherapy Failure in Patients With Natural Killer/T-Cell Lymphoma.American journal of hematology · 2026Article
- Development and validation of a radiomics nomogram for predicting outcomes following combined radiotherapy and modern chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: a multicenter study.Annals of hematology · 2026Article
- Prognostic value of lesion dissemination onQuantitative imaging in medicine and surgery · 2026Article
- Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma.Blood advances · 2026Article
- Prognostic significance of quantitative EBV biomarkers in extranodal NK/T-cell lymphoma: a meta-analysis of EBV DNA load and EBER-positive cell proportion.Infectious agents and cancer · 2026Review
- An inflammation-integrated prognostic nomogram for advanced-stage extranodal NK/T-cell lymphoma: a multicenter retrospective study.Annals of hematology · 2026Article
- A revised staging system for natural killer/T cell lymphoma incorporating skull base invasion and nasal/non-nasal subtype distinction.Cell reports. Medicine · 2026Article
- IFN-γ Driven Hepatic Injury Exacerbates Mortality in NK/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis.Cancer medicine · 2026Article
- The prognostic predictive SER model for NK/T-cell lymphoma in the era of modern immunotherapy.Cancer cell international · 2026Article
- Immune-Mediated IgA Nephropathy Induced by PD-1 Blockade in Extranodal NK/T-Cell Lymphoma.International medical case reports journal · 2026Article
- Serum triglyceride and apolipoprotein A1 as dynamic biomarkers in extranodal NK/T-cell lymphoma (ENKTL): A multicenter retrospective and prospective validation study.Annals of hematology · 2025Article
- Prognostic value of the co-stimulatory molecule OX40 expression in Extranodal Natural Killer/T-cell Lymphoma.Annals of medicine · 2025Article
- Radiotherapy alone versus combined therapy in stage I natural killer/T-cell lymphoma: impact of local invasion on treatment outcomes.Clinical and experimental medicine · 2025Article
- A novel prognostic model based on CA stage for enhanced stratification and survival prediction in patients with Natural killer/T-cell lymphoma.Annals of hematology · 2025Article
- The prognostic value of lactate dehydrogenase/albumin ratio in extranodal natural killer/T cell lymphoma.BMC cancer · 2025Article
- Safety of low-dose radiotherapy in newly diagnosed stage I/II extranodal NK/T-cell lymphoma: a single-center retrospective analysis.Annals of hematology · 2025Article
- Prognostic value of the pre-treatment SUVmax ofCancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 20 institutions in 3 countries.
Funding
Abstract
Derived from our original nomogram study by using the risk variables from multivariable analyses in the derivation cohort of 1383 patients with extranodal NK/T-cell lymphoma, nasal-type (ENKTCL) who were mostly treated with anthracycline-based chemotherapy, we propose an easily used nomogram-revised risk index (NRI), validated it and compared with Ann Arbor staging, the International Prognostic Index (IPI), Korean Prognostic Index (KPI), and prognostic index of natural killer lymphoma (PINK) for overall survival (OS) prediction by examining calibration, discrimination, and decision curve analysis in a validation cohort of 1582 patients primarily treated with non-anthracycline-based chemotherapy. The calibration of the NRI showed satisfactory for predicting 3- and 5-year OS in the validation cohort. The Harrell's C-index and integrated Brier score (IBS) of the NRI for OS prediction demonstrated a better performance than that of the Ann Arbor staging system, IPI, KPI, and PINK. Decision curve analysis of the NRI also showed a superior outcome. The NRI is a promising tool for stratifying patients with ENKTCL into risk groups for designing clinical trials and for selecting appropriate individualized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.